secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2021-11-03T23:59:59+00:00
Accession:  0000950170-21-002863
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics prices $125M public offering of 35.7M shares at $3.50; uplists to Nasdaq
--------------------------------------------------------------------------------

- Underwritten public offering of 35,715,000 shares at $3.50/share; underwriters have 30-day option for additional 5,357,250 shares.
- Gross proceeds ~$125M; net proceeds after discounts and expenses ~$117.3M.
- Common stock to trade on Nasdaq Capital Market under ticker CMPX starting November 2, 2021.
- SVB Leerink is book-running manager; Raymond James, Wedbush, H.C. Wainwright as passive book-runners.
- Net proceeds to fund ongoing operations including clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000095017021002863/0000950170-21-002863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000095017021002863/cmpx-20211101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-002863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer